EcoDrugPlus

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSGACG00000006035
Gene Symbol: CHRM5A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSGACG00000007923
Gene Symbol: CHRM5B
1 Cross references
190 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSGACG00000004655
Gene Symbol: CHRNA4B
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSGACG00000016966
Gene Symbol: CHRNA7A
1 Cross references
208 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSGACG00000010138
Gene Symbol: F2R
1 Cross references
211 Possible Orthologues:

Coagulation Factor Iiia

Ensembl ID : ENSGACG00000000087
Gene Symbol: F3A
1 Cross references
199 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSGACG00000015474
Gene Symbol: F10
1 Cross references
246 Possible Orthologues:

Coiled-Coil Domain Containing 6a

Ensembl ID : ENSGACG00000009958
Gene Symbol: CCDC6A
1 Cross references
208 Possible Orthologues:

Colony Stimulating Factor 1 Receptor, A

Ensembl ID : ENSGACG00000018007
Gene Symbol: CSF1RA
1 Cross references
207 Possible Orthologues:

Corticotropin Releasing Hormone Receptor 1

Ensembl ID : ENSGACG00000004272
Gene Symbol: CRHR1
1 Cross references
209 Possible Orthologues:

Cyclin D1

Ensembl ID : ENSGACG00000014165
Gene Symbol: CCND1
1 Cross references
231 Possible Orthologues:

Cyclin-Dependent Kinase 1

Ensembl ID : ENSGACG00000002518
Gene Symbol: CDK1
1 Cross references
246 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).